期刊
JOURNAL OF DIABETES INVESTIGATION
卷 8, 期 1, 页码 123-125出版社
WILEY
DOI: 10.1111/jdi.12600
关键词
Diabetes mellitus; HbA1c; Kumamoto Declaration 2013
资金
- Astellas Pharma Inc.
- Takeda Pharmaceutical Company Limited.
- Mitsubishi Tanabe Pharma Corporation
- Daiichi Sankyo Company, Limited
- Taisho Pharmaceutical Holdings Co., Ltd.
- Ono Pharmaceutical Co., LTD.
- MSD
- Grants-in-Aid for Scientific Research [26000012, 15K09394, 15K15348] Funding Source: KAKEN
In the 'Evidence-based Practice Guideline for the Treatment for Diabetes in Japan 2013', a new concept of the glycemic control in patients with diabetes in Japan has been declared from the Japan Diabetes Society. The main objective value of HbA1c was set to <7% from the perspective of preventing microvascular complications. On the other hand, the objective in cases where objectives can be attained by appropriate dietary or exercise therapy, or during pharmacotherapy without the occurrence of side effects such as hypoglycemia was set to <6%, and the objective in cases where intensification of treatment was considered difficult due to side effects such as hypoglycemia or for other reasons was set to <8%. Treatment objectives should be established individually, in consideration of age, duration of disease, organ damage, risk of hypoglycemia, support structure, and etc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据